Acquired Autoimmune Factor XIII Deficiency as a Novel Immune-Related Adverse Event of Combined Ipilimumab and Nivolumab Therapy for Renal Cell Carcinoma: A Case Report
{{output}}
Introduction: Combination therapy with immune checkpoint inhibitors (ICIs) has become the standard pharmacological treatment for renal cell carcinoma; however, careful attention must be paid to immune-related adverse events (irAE... ...
